Loading clinical trials...
Loading clinical trials...
An Open-label, Single-arm, Multicenter, Phase II Clinical Study of Surufatinib Plus Cadonilimab as Second-line Therapy in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma
Conditions
Interventions
surufatinib plus cadonilimab
Locations
1
China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Start Date
October 30, 2023
Primary Completion Date
October 1, 2024
Completion Date
October 31, 2025
Last Updated
October 23, 2023
Lead Sponsor
Zhejiang Cancer Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions